Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
67392-87-4
Molecular formula
C24H30O3
Molecular weight
366.5 g/mol
Drug class
Synthetic progestogenprogesterone receptor agonist with antimineralocorticoid and antiandrogenic activity
Mechanism of action
Activates progesterone receptors to suppress gonadotropin secretion and ovulation and also antagonises mineralocorticoid and androgen receptors, contributing to antimineralocorticoid and antiandrogenic effects.
Indications / reported uses
Component of combined oral contraceptive products for prevention of pregnancy
Used in selected hormone therapy combinations to oppose oestrogen effects on the endometrium; drospirenone-only and combination-product indications differ by jurisdiction
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Drospirenone Environmental Risk Assessment (ERA) (the Drospirenone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.